Celecoxib is an approved COX2 inhibitor in ovarian cancer and celecoxib-mediated COX2 blockade was observed to reverse MDSC suppressive function in an in vitro patient-derived culture assay. The gene discussed is PTGS2; the disease is ovarian cancer.